JP2015078220A5 - - Google Patents

Download PDF

Info

Publication number
JP2015078220A5
JP2015078220A5 JP2014249071A JP2014249071A JP2015078220A5 JP 2015078220 A5 JP2015078220 A5 JP 2015078220A5 JP 2014249071 A JP2014249071 A JP 2014249071A JP 2014249071 A JP2014249071 A JP 2014249071A JP 2015078220 A5 JP2015078220 A5 JP 2015078220A5
Authority
JP
Japan
Prior art keywords
clostridium difficile
caused
composition
bibenzo
pyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014249071A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015078220A (ja
Filing date
Publication date
Priority claimed from GBGB0821913.1A external-priority patent/GB0821913D0/en
Application filed filed Critical
Publication of JP2015078220A publication Critical patent/JP2015078220A/ja
Publication of JP2015078220A5 publication Critical patent/JP2015078220A5/ja
Pending legal-status Critical Current

Links

JP2014249071A 2008-12-02 2014-12-09 抗細菌化合物 Pending JP2015078220A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0821913.1A GB0821913D0 (en) 2008-12-02 2008-12-02 Antibacterial compounds
GB0821913.1 2008-12-02

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2011538052A Division JP5665756B2 (ja) 2008-12-02 2009-12-01 抗細菌化合物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016212160A Division JP2017048217A (ja) 2008-12-02 2016-10-28 抗細菌化合物

Publications (2)

Publication Number Publication Date
JP2015078220A JP2015078220A (ja) 2015-04-23
JP2015078220A5 true JP2015078220A5 (https=) 2015-12-24

Family

ID=40262471

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2011538052A Active JP5665756B2 (ja) 2008-12-02 2009-12-01 抗細菌化合物
JP2014249071A Pending JP2015078220A (ja) 2008-12-02 2014-12-09 抗細菌化合物
JP2016212160A Pending JP2017048217A (ja) 2008-12-02 2016-10-28 抗細菌化合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2011538052A Active JP5665756B2 (ja) 2008-12-02 2009-12-01 抗細菌化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016212160A Pending JP2017048217A (ja) 2008-12-02 2016-10-28 抗細菌化合物

Country Status (27)

Country Link
US (3) US8975416B2 (https=)
EP (3) EP2373631B1 (https=)
JP (3) JP5665756B2 (https=)
KR (1) KR101643435B1 (https=)
CN (1) CN102227411B (https=)
AU (1) AU2009323854B2 (https=)
BR (2) BRPI0922220B8 (https=)
CA (1) CA2744962C (https=)
CY (2) CY1116383T1 (https=)
DK (2) DK2373631T3 (https=)
ES (2) ES2537059T3 (https=)
GB (1) GB0821913D0 (https=)
HR (2) HRP20150518T1 (https=)
HU (1) HUE029151T2 (https=)
IL (1) IL213325A (https=)
LT (1) LT2907813T (https=)
MX (1) MX2011005837A (https=)
NZ (1) NZ593111A (https=)
PL (2) PL2373631T3 (https=)
PT (2) PT2373631E (https=)
RS (1) RS54904B1 (https=)
RU (1) RU2525915C2 (https=)
SG (1) SG171939A1 (https=)
SI (2) SI2373631T1 (https=)
SM (2) SMT201500117B (https=)
WO (1) WO2010063996A2 (https=)
ZA (1) ZA201103751B (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0821913D0 (en) * 2008-12-02 2009-01-07 Price & Co Antibacterial compounds
GB2480816A (en) * 2010-06-01 2011-12-07 Summit Corp Plc Compounds for the treatment of Clostridium difficile associated diseases
GB2480813A (en) * 2010-06-01 2011-12-07 Summit Corp Plc Compounds for the treatment of clostridium difficile-associated disease
ES2803556T3 (es) 2010-06-01 2021-01-27 Summit Oxford Ltd Compuestos para el tratamiento de enfermedades asociadas a clostridium difficile
WO2011151620A1 (en) * 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile associated disease
GB2480814A (en) * 2010-06-01 2011-12-07 Summit Corp Plc Compounds for the treatment of clostridium difficile-associated disease
WO2011151619A1 (en) * 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile associated disease
US9079935B2 (en) 2012-08-13 2015-07-14 The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Las Vegas Reducing risk of contracting Clostridium-difficile associated disease
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
SG11201503966PA (en) 2012-11-23 2015-06-29 Seres Health Inc Synergistic bacterial compositions and methods of production and use thereof
JP2016509003A (ja) 2013-02-04 2016-03-24 セレス セラピューティクス インコーポレイテッド 組成物および方法
US10973861B2 (en) 2013-02-04 2021-04-13 Seres Therapeutics, Inc. Compositions and methods
WO2014145958A2 (en) 2013-03-15 2014-09-18 Seres Health, Inc. Network-based microbial compositions and methods
CN105979952B (zh) 2013-11-25 2022-04-08 赛里斯治疗公司 协同细菌组合物以及其制造方法和用途
US9956282B2 (en) 2013-12-16 2018-05-01 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
JP6526956B2 (ja) * 2013-12-19 2019-06-05 花王株式会社 固形状組成物
US9717711B2 (en) 2014-06-16 2017-08-01 The Lauridsen Group Methods and compositions for treating Clostridium difficile associated disease
WO2016127102A2 (en) 2015-02-06 2016-08-11 Ernesto Abel-Santos Inhibiting germination of clostridium perfringens spores to reduce necrotic enteritis
EP3668527A1 (en) 2017-08-14 2020-06-24 Seres Therapeutics, Inc. Compositions and methods for treating cholestatic disease
WO2019068383A1 (en) * 2017-10-05 2019-04-11 Sandoz Ag PROCESS FOR THE PREPARATION OF RIDINILAZOLE USING ACID ADDITION SALTS
BR112020008552A2 (pt) 2017-10-30 2020-12-29 Seres Therapeutics, Inc. métodos e composições para tratamento de resistência a antibiótico
IL289453B2 (en) 2019-07-17 2026-03-01 Summit Oxford Ltd Process for preparing ridinilazole and its crystalline forms
BR112022010924A2 (pt) 2019-12-06 2022-09-06 Vertex Pharma Tetra-hidrofuranos substituídos como moduladores de canais de sódio
US20210324009A1 (en) * 2020-04-17 2021-10-21 The University Of Hong Kong Anti-bacterial calcium-dependent antibiotic (cda) analogs and methods of treating bacterial infections
GB202100470D0 (en) * 2021-01-14 2021-03-03 Summit Oxford Ltd Solid tablet dosage for of ridinilazole
GB202100471D0 (en) 2021-01-14 2021-03-03 Summit Oxford Ltd Preparation of antibacterial compounds
MX2023013980A (es) * 2021-05-24 2024-03-05 Aimmax Therapeutics Inc Combinaciones de pristinamicina ia y flopristin para el tratamiento o prevencion de infecciones bacterianas.
SMT202500481T1 (it) 2021-06-04 2026-01-12 Vertex Pharma N-(idrossialchil(etero)aril)tetraidrofuran carbossammidi come modulatori di canali del sodio
US20240300939A1 (en) 2021-06-14 2024-09-12 Scorpion Therapeutics, Inc. Urea derivatives which can be used to treat cancer
WO2023039159A2 (en) 2021-09-09 2023-03-16 Abel Santos Ernesto Inhibitors of c. difficile spore germination
WO2024112631A1 (en) * 2022-11-22 2024-05-30 Aimmax Therapeutics, Inc. Streptogramin a monotherapy for treating or preventing bacterial infections
EP4418810A1 (de) 2023-02-15 2024-08-21 Siemens Aktiengesellschaft Verfahren zur rechnergestützten überwachung einer industriellen anlage mittels eines funknetzes

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3661849A (en) * 1965-10-06 1972-05-09 Ashland Oil Inc Heterocyclic polyimides prepared from heterocyclic diamines
US3503929A (en) 1965-10-21 1970-03-31 Minnesota Mining & Mfg Polyimidazoquinazolines and polyamidobenzimidazoles
DE1670684A1 (de) 1966-04-01 1970-12-03 Hoechst Ag Verfahren zur Herstellung von basisch substituierten Bis-benzimidazol-derivaten
US4087409A (en) * 1966-11-07 1978-05-02 Monsanto Company Ordered heterocyclic copolymers
JPS50140445A (https=) * 1974-04-30 1975-11-11
JPS50154250A (https=) * 1974-05-31 1975-12-12
US5089592A (en) 1988-06-09 1992-02-18 The Dow Chemical Company Biscyclobutarene monomer comprising two cyclobutarene moieties bridged by a divalent radical comprising at least one benzothiazole or benzimidazole linkage
JPH03500661A (ja) * 1988-06-09 1991-02-14 ザ・ダウ・ケミカル・カンパニー ベンゾキサゾール，ベンゾチアゾールまたはベンズイミダゾールの少なくとも１つの結合によって架橋したビスシクロブタレンのモノマー，オリゴマー及びポリマー
GB9108279D0 (en) 1991-04-18 1991-06-05 Ucb Sa A method of preparing 1h-benzimidazoles
US5317078A (en) * 1991-10-30 1994-05-31 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Polybenzimidazole via aromatic nucleophilic displacement
CN1164227A (zh) * 1994-11-17 1997-11-05 弗·哈夫曼-拉罗切有限公司 联苯并咪唑衍生物
US5824698A (en) * 1994-11-17 1998-10-20 Hoffman-La Roche Inc. Antibacterial dibenzimidazole derivatives
US5770617A (en) 1996-03-20 1998-06-23 Rutgers, The State University Of New Jersey Terbenzimidazoles useful as antifungal agents
JPH11158156A (ja) 1997-12-03 1999-06-15 Earth Chem Corp Ltd 新規な１−（４−アルキルオキシフェニル）イミダゾール化合物
JPH11158158A (ja) * 1997-12-03 1999-06-15 Snow Brand Milk Prod Co Ltd 新規ベンゾイミダゾール誘導体
US6358930B1 (en) 1998-05-28 2002-03-19 Synsorb Biotech Inc. Treatment of C. difficile toxin B associated conditions
JP2000095767A (ja) * 1998-09-28 2000-04-04 Takeda Chem Ind Ltd 性腺刺激ホルモン放出ホルモン拮抗剤
GB9908828D0 (en) 1999-04-16 1999-06-16 Univ Reading The Compounds
ES2232683T3 (es) 2000-11-27 2005-06-01 Ciba Specialty Chemicals Holding Inc. Derivados de 2-(2-hiddroxifenil)-2h-benzotriazoles, sustituidos en posicion 5 por arilo y en posicion 5 por heteroarilo, como absorbentes uv.
DE60131015T2 (de) 2000-12-15 2008-07-10 Vertex Pharmaceuticals Inc., Cambridge Bakterielle gyrase-hemmer und deren verwendung
FR2819180B1 (fr) 2001-01-11 2003-02-21 Oreal Composition photoprotectrices a base de polymeres amphiphiles d'au moins un monomere a insaturation ethylique a groupement sulfonique et comportant une partie hydrophobe
AU2002228317A1 (en) * 2001-01-29 2002-08-12 Insight Strategy And Marketing Ltd Benz-1,3-azole derivatives and their uses as heparanase inhibitors
WO2004001058A2 (en) 2001-05-04 2003-12-31 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
AU2002317377A1 (en) * 2001-07-20 2003-03-03 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
BR0213562A (pt) 2001-10-26 2004-08-31 Aventis Pharma Inc Benzimidazóis e análogos e seu uso como inibidores de cinases de proteìna
PL374191A1 (en) 2002-06-13 2005-10-03 Vertex Pharmaceuticals Incorporated 2-ureido-6-heteroaryl-3h-benzoimidazole-4-carboxylic acid derivatives and related compounds as gyrase and/or topoisomerase iv inhibitors for the treatment of bacterial infections
EP1547996A4 (en) * 2002-08-30 2006-08-02 Bf Res Inst Inc DIAGNOSTIC PROBES AND REMEDIES FOR DISEASES IN WHICH PRION PROTEIN IS ACCUMULATED, AND ANIMAL FEVERING FOR PRION PROTEIN
EP1558341A4 (en) 2002-11-01 2010-09-08 Paratek Pharm Innc TRANSCRIPTION FACTOR MODULATING CONNECTIONS AND THEIR USE
JP2008504233A (ja) 2004-04-23 2008-02-14 パラテック ファーマシューティカルズ インコーポレイテッド 転写因子調節化合物およびその使用法
KR100629060B1 (ko) 2004-08-11 2006-09-26 주식회사 엘지화학 새로운 벤즈이미다졸계 화합물
PT1812440E (pt) 2004-11-04 2011-01-25 Vertex Pharma Pirazolo[1,5-a]pirimidinas úteis enquanto inibidores de proteínas cinases
CA2594665A1 (en) 2005-01-19 2006-07-27 Biolipox Ab Thienopyrroles useful in the treatment of inflammation
US7825154B2 (en) 2005-08-12 2010-11-02 The United States Of America As Represented By The Secretary Of The Army Small molecule inhibitors of botulinum neurotoxins
JP2009514894A (ja) 2005-11-07 2009-04-09 バーテックス ファーマシューティカルズ インコーポレイテッド ジャイレース阻害剤としてのベンズイミダゾール誘導体
KR100744827B1 (ko) * 2006-04-05 2007-08-01 한국화학연구원 트리플루오로비닐옥시기를 포함하는 불소계 벤즈이미다졸 단량체 및 이의 제조방법
GB0612428D0 (en) 2006-06-22 2006-08-02 Prolysis Ltd Antibacterial agents
BRPI0716239A2 (pt) 2006-08-30 2013-08-13 Cellzome Ltd derivados de triazol como inibidores de cinase
AR063311A1 (es) * 2006-10-18 2009-01-21 Novartis Ag Compuestos organicos
WO2008073451A2 (en) 2006-12-11 2008-06-19 Sirtris Pharmaceuticals, Inc. Benzoimidazole derivatives as sirtuin (sir) modulating compounds
CA2672815A1 (en) 2006-12-15 2008-06-26 Pfizer Products Inc. Benzimidazole derivatives for use in treating abnormal cell growth
WO2009147189A1 (en) 2008-06-05 2009-12-10 Glaxo Group Limited Novel compounds
US7906655B2 (en) 2008-08-07 2011-03-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
KR101022649B1 (ko) 2008-08-07 2011-03-22 삼성모바일디스플레이주식회사 헤테로고리 화합물 및 이를 이용한 유기 전계 발광 장치
GB0821913D0 (en) * 2008-12-02 2009-01-07 Price & Co Antibacterial compounds
RU2544010C2 (ru) 2009-02-27 2015-03-10 Энанта Фармасьютикалс, Инк. Ингибиторы вируса гепатита с
KR101219487B1 (ko) 2009-03-03 2013-01-15 덕산하이메탈(주) 비스벤조이미다졸 화합물 및 이를 이용한 유기전기소자, 그단말
NZ595674A (en) 2009-04-02 2012-12-21 Ct Nac Investigaciones Oncologicas Cnio Imidazo[2,1-b][1,3,4]thiadiazole derivatives
JP2012528174A (ja) 2009-05-27 2012-11-12 アボット・ラボラトリーズ キナーゼ活性のピリミジン阻害剤
JP2012528195A (ja) 2009-05-29 2012-11-12 メルク・シャープ・アンド・ドーム・コーポレーション Ｃ型肝炎などの疾患を処置するための３つの結合アリール部分で構成された抗菌性化合物
WO2010147898A2 (en) 2009-06-15 2010-12-23 Rigel Pharmaceuticals, Inc. Small molecule inhibitors of spleen tyrosine kinase (syk)
WO2011046954A1 (en) 2009-10-13 2011-04-21 Ligand Pharmaceuticals Inc. Hematopoietic growth factor mimetic small molecule compounds and their uses
ES2803556T3 (es) 2010-06-01 2021-01-27 Summit Oxford Ltd Compuestos para el tratamiento de enfermedades asociadas a clostridium difficile

Similar Documents

Publication Publication Date Title
JP2015078220A5 (https=)
JOP20210109B1 (ar) مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
WO2017087608A8 (en) Modulators of ror-gamma
EA033544B1 (ru) Производные пиридона в качестве ингибиторов киназы, реаранжированной во время трансфекции (ret)
JP2016515522A5 (https=)
WO2015200481A8 (en) Mnk inhibitors and methods related thereto
NZ724578A (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
SG10201902598VA (en) Peptidomimetic macrocycles and formulations thereof
UA114906C2 (uk) Гетероциклільні сполуки як інгібітори мек
IL295418B1 (en) Beta-d-2'-deoxy-2' alpha-fluoro-2'-bata-c-modified-2-different-n6-purine modified nucleotides for the treatment of hepatitis c virus
HUE052332T2 (hu) Heteroaril-származék vagy gyógyászatilag elfogadható sója, eljárás annak elõállítására, és az ezeket hatóanyagént tartalmazó gyógyászati készítmény PI3 kinázokkal összefüggõ betegségek megelõzésére vagy kezelésére
PH12016502103A1 (en) Novel disubstituted 1,2, 4-triazine compound
HK1217092A1 (zh) 治疗性化合物及其用途
PH12017500089B1 (en) Aldosterone synthase inhibitors
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
WO2016010869A3 (en) FUSED QUINOLINE COMPUNDS AS PI3K, mTOR INHIBITORS
WO2015173701A3 (en) Pharmaceutical compositions comprising danirixin for treating infectious diseases
WO2016011049A3 (en) Compositions and methods for disease treatment using nanoparticle delivered compounds
CN109689652A (zh) 稠杂环类衍生物、其制备方法及其在医学上的应用
PH12016500042A1 (en) Stabilized pharmaceutical dosage forms comprising atrasentan
PH12018500358A1 (en) Compounds for use in an antibacterial applications
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
WO2016006974A3 (en) Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
EA201692518A3 (ru) Способы улучшения производительности миокарда у пациентов после операции фонтена с применением композиций уденафила
EA201792265A1 (ru) Способы лечения сердечно-сосудистых заболеваний